Grass Pollen Allergy – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Grass Pollen Allergy – Pipeline Review, H1 2017’, provides an overview of the Grass Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Grass Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy

– The report reviews pipeline therapeutics for Grass Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Grass Pollen Allergy therapeutics and enlists all their major and minor projects

– The report assesses Grass Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Grass Pollen Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ALK-Abello A/S

Allergy Therapeutics Plc

Biomay AG

HAL Allergy BV

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Grass Pollen Allergy - Overview

Grass Pollen Allergy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Grass Pollen Allergy - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Grass Pollen Allergy - Companies Involved in Therapeutics Development

ALK-Abello A/S

Allergy Therapeutics Plc

Biomay AG

HAL Allergy BV

Grass Pollen Allergy - Drug Profiles

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-32 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Grass - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine 1 for Grass Pollen Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Grass Pollen Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Grass Pollen Allergy - Dormant Projects

Grass Pollen Allergy - Product Development Milestones

Featured News & Press Releases

Jan 26, 2017: Biomay AG Reports Positive Results From A Second Phase IIb Trial With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32

Sep 08, 2016: Grass pollen allergy vaccine also effective against hepatitis B

Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204

Jun 13, 2016: New Data From GAP Landmark Trial Confirm GRAZAX Prevents Asthma Symptoms in Children

Mar 04, 2016: Inflamax Research Announces the Successful Completion of Enrollment for the First Multi-center, Mobile Environmental Exposure Chamber (mEEC) Study

Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL

Jan 28, 2016: Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32

Jan 14, 2016: ALK announces top-line results from the five-year landmark GRAZAX Asthma Prevention trial in children

Jun 03, 2015: Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference.

Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32

Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK

Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study

Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)

Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32

Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Grass Pollen Allergy, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Grass Pollen Allergy – Pipeline by ALK-Abello A/S, H1 2017

Grass Pollen Allergy – Pipeline by Allergy Therapeutics Plc, H1 2017

Grass Pollen Allergy – Pipeline by Biomay AG, H1 2017

Grass Pollen Allergy – Pipeline by HAL Allergy BV, H1 2017

Grass Pollen Allergy – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Grass Pollen Allergy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports